0000849636 false 0000849636 2021-11-17 2021-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549




Current Report


Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 17, 2021



(Exact name of registrant as specified in its charter)


Delaware   1-16467   33-0303583

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S Employer

Identification No.)


126 Valley Road, Suite C

Glen Rock, New Jersey

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (201) 444-4947



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 7.01 Regulation FD Disclosure


On November 22, 2021, RespireRx Pharmaceuticals Inc. (the “Company”) announced that a podcast interview hosted by the OTC Markets of the Company’s Chief Executive Officer and President, Timothy Jones, recorded on October 21, 2021, was made available to the general public on November 17, 2021.


The interview is part of the OTCQB, the OTC Venture Market, Podcast series (Season 5, Episode 44), and appears on the OTC Markets podcast page. A link to the podcast will also be available on the Company’s website, on Apple Podcasts, on Stitcher, and on Google Podcasts.


The podcast has also been shared on the OTC Market’s below social media channels










The press release announcing the Podcast is attached as Exhibit 99.1.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits.


A list of the exhibit that is furnished and not filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.






Exhibit Number   Exhibit Description
99.1   Press Release dated November 22, 2021*
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)


* Furnished herewith.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Jeff E. Margolis
    Jeff E. Margolis
    Vice President, Treasurer and Secretary




RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.